Spero Therapeutics Inc

Insider sell‑to‑cover on Spero Therapeutics raises questions about liquidity and near‑term outlook—focus on upcoming Q1 results and clinical milestones.

Insider buys signal Spero’s COO confidence in MDR‑bacteria pipeline, hinting at long‑term upside despite short‑term price dips.

Insider Rajavelu Esther’s bulk Spero Therapeutics share buy‑sell reveals confidence in its MDR‑bacteria pipeline, balancing tax cover with long‑term investment.